Chemokine Heteromers and Their Impact on Cellular Function—A Conceptual Framework

Chemoattractant cytokines or chemokines are proteins involved in numerous biological activities. Their essential role consists of the formation of gradient and (immune) cell recruitment. Chemokine biology and its related signaling system is more complex than simple ligand–receptor interactions. Beside interactions with their cognate and/or atypical chemokine receptors, and glycosaminoglycans (GAGs), chemokines form complexes with themselves as homo-oligomers, heteromers and also with other soluble effector proteins, including the atypical chemokine MIF, carbohydrate-binding proteins (galectins), damage-associated molecular patterns (DAMPs) or with chemokine-binding proteins such as evasins. Likewise, nucleic acids have been described as binding targets for the tetrameric form of CXCL4. The dynamic balance between monomeric and dimeric structures, as well as interactions with GAGs, modulate the concentrations of free chemokines available along with the nature of the gradient. Dimerization of chemokines changes the canonical monomeric fold into two main dimeric structures, namely CC- and CXC-type dimers. Recent studies highlighted that chemokine dimer formation is a frequent event that could occur under pathophysiological conditions. The structural changes dictated by chemokine dimerization confer additional biological activities, e.g., biased signaling. The present review will provide a short overview of the known functionality of chemokines together with the consequences of the interactions engaged by the chemokines with other proteins. Finally, we will present potential therapeutic tools targeting the chemokine multimeric structures that could modulate their biological functions.

[1]  M. Bianchi,et al.  The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with chemokine CXCL12 , 2023, bioRxiv.

[2]  M. Uguccioni,et al.  The chemokine landscape: one system multiple shades , 2023, Frontiers in Immunology.

[3]  I. Schiessl,et al.  Chemokine CXCL4 interactions with extracellular matrix proteoglycans mediate widespread immune cell recruitment independent of chemokine receptors. , 2023, Cell reports.

[4]  R. Lande,et al.  CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells , 2022, International journal of molecular sciences.

[5]  A. Gottlieb,et al.  Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) , 2022, The Lancet.

[6]  B. Volkman,et al.  A new obligate CXCL4–CXCL12 heterodimer for studying chemokine heterodimer activities and mechanisms , 2022, Scientific Reports.

[7]  R. Koenen,et al.  Galectokines: The Promiscuous Relationship between Galectins and Cytokines , 2022, Biomolecules.

[8]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[9]  Y. Döring,et al.  Targeting platelet-derived CXCL12 impedes arterial thrombosis. , 2022, Blood.

[10]  J. Bernhagen,et al.  Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation , 2021, Cellular and Molecular Life Sciences.

[11]  K. Wichapong,et al.  The marriage of chemokines and galectins as functional heterodimers , 2021, Cellular and Molecular Life Sciences.

[12]  B. Volkman,et al.  The dimeric form of CXCL12 binds to atypical chemokine receptor 1 , 2021, Science Signaling.

[13]  Wing Yee Lai,et al.  Latest update on chemokine receptors as therapeutic targets , 2021, Biochemical Society transactions.

[14]  J. Galipeau Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity , 2021, Stem cells.

[15]  R. Koenen,et al.  Chemokines modulate glycan binding and the immunoregulatory activity of galectins , 2021, Communications Biology.

[16]  K. Rajarathnam,et al.  Structural Basis of a Chemokine Heterodimer Binding to Glycosaminoglycans. , 2021, The Biochemical journal.

[17]  R. Koenen,et al.  Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro , 2021, PloS one.

[18]  C. Rüegg,et al.  β-Arrestin1 and β-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4 , 2020, Frontiers in Immunology.

[19]  K. Pahan,et al.  IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE , 2020, Proceedings of the National Academy of Sciences.

[20]  S. Bhattacharya,et al.  Engineered anti-inflammatory peptides inspired by mapping an evasin–chemokine interaction , 2020, The Journal of Biological Chemistry.

[21]  R. Gazzinelli,et al.  CCL3/Macrophage Inflammatory Protein-1α Is Dually Involved in Parasite Persistence and Induction of a TNF- and IFNγ-Enriched Inflammatory Milieu in Trypanosoma cruzi-Induced Chronic Cardiomyopathy , 2020, Frontiers in Immunology.

[22]  Gary D Bader,et al.  A reference map of the human binary protein interactome , 2020, Nature.

[23]  O. Soehnlein,et al.  Chemokines and galectins form heterodimers to modulate inflammation , 2020, EMBO reports.

[24]  R. Koenen,et al.  Tick Saliva Protein Evasin-3 Allows for Visualization of Inflammation in Arteries through Interactions with CXC-Type Chemokines Deposited on Activated Endothelium , 2020, Bioconjugate chemistry.

[25]  J. Galipeau,et al.  CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury , 2020, Cell reports.

[26]  L. Rauova,et al.  CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. , 2019, Cellular signalling.

[27]  R. Koenen,et al.  Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2 , 2019, The Journal of Biological Chemistry.

[28]  Ernest Y Lee,et al.  CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis , 2019, Nature Communications.

[29]  M. Bianchi,et al.  Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment , 2019, bioRxiv.

[30]  A. Cavalli,et al.  Oxidation State Dependent Conformational Changes of HMGB1 Regulate the Formation of the CXCL12/HMGB1 Heterocomplex , 2019, bioRxiv.

[31]  M. Uguccioni,et al.  Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity , 2018, Front. Immunol..

[32]  B. Volkman,et al.  The Solution Structure of CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity. , 2018, Journal of molecular biology.

[33]  R. Koenen,et al.  Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis , 2018, Scientific Reports.

[34]  J. Fox,et al.  CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration , 2018, Scientific Reports.

[35]  C. Billottet,et al.  Oligomerization State of CXCL4 Chemokines Regulates G Protein-Coupled Receptor Activation. , 2017, ACS chemical biology.

[36]  K. Rajarathnam,et al.  Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil–Platelet Crosstalk , 2017, Front. Immunol..

[37]  U. Desai,et al.  FIGURES FOR : Solution structure of CXCL 13 and heparan sulfate binding show that GAG binding site and cellular signalling rely on distinct domains , 2017 .

[38]  A. Valente,et al.  Insights into CC Chemokine Ligand 2/Chemokine Receptor 2 Molecular Recognition: A Step Forward toward Antichemotactic Agents. , 2017, Biochemistry.

[39]  R. Koenen,et al.  Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation , 2017, Science Translational Medicine.

[40]  K. Rajarathnam,et al.  Chemokine CXCL7 Heterodimers: Structural Insights, CXCR2 Receptor Function, and Glycosaminoglycan Interactions , 2017, International journal of molecular sciences.

[41]  K. Rajarathnam,et al.  Structural Basis of Native CXCL7 Monomer Binding to CXCR2 Receptor N-Domain and Glycosaminoglycan Heparin , 2017, International journal of molecular sciences.

[42]  R. Koenen,et al.  Probing Functional Heteromeric Chemokine Protein–Protein Interactions through Conformation‐Assisted Oxime Ligation , 2016, Angewandte Chemie.

[43]  Baohui Xu,et al.  MKEY, a Peptide Inhibitor of CXCL4‐CCL5 Heterodimer Formation, Protects Against Stroke in Mice , 2016, Journal of the American Heart Association.

[44]  Kai A. Kropp,et al.  Chemokine binding proteins: An immunomodulatory strategy going viral. , 2016, Cytokine & growth factor reviews.

[45]  A. Dinner,et al.  Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3 , 2016, Proceedings of the National Academy of Sciences.

[46]  D. Fremont,et al.  Parallel Evolution of Chemokine Binding by Structurally Related Herpesvirus Decoy Receptors. , 2016, Structure.

[47]  K. Rajarathnam,et al.  CXCL1/MGSA Is a Novel Glycosaminoglycan (GAG)-binding Chemokine , 2015, The Journal of Biological Chemistry.

[48]  C. Weber,et al.  Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5 , 2015, Science Translational Medicine.

[49]  T. Handel,et al.  The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. , 2015, Glycobiology.

[50]  R. Couñago,et al.  Structures of Orf Virus Chemokine Binding Protein in Complex with Host Chemokines Reveal Clues to Broad Binding Specificity. , 2015, Structure.

[51]  J. Prestegard,et al.  Interactions of the Chemokine CCL5/RANTES with Medium-Sized Chondroitin Sulfate Ligands. , 2015, Structure.

[52]  E. García-Zepeda,et al.  Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents , 2015, International journal of molecular sciences.

[53]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[54]  I. Štibrániová,et al.  Tick salivary compounds: their role in modulation of host defences and pathogen transmission , 2013, Front. Cell. Infect. Microbiol..

[55]  M. Lotze,et al.  HMGB1 in Cancer: Good, Bad, or Both? , 2013, Clinical Cancer Research.

[56]  Baohui Xu,et al.  Peptide Inhibitor of CXCL4–CCL5 Heterodimer Formation, MKEY, Inhibits Experimental Aortic Aneurysm Initiation and Progression , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[57]  K. Rajarathnam,et al.  Chemokine CXCL1 Dimer Is a Potent Agonist for the CXCR2 Receptor* , 2013, The Journal of Biological Chemistry.

[58]  R. Linhardt,et al.  Heparin Oligosaccharides Inhibit Chemokine (CXC Motif) Ligand 12 (CXCL12) Cardioprotection by Binding Orthogonal to the Dimerization Interface, Promoting Oligomerization, and Competing with the Chemokine (CXC Motif) Receptor 4 (CXCR4) N Terminus* , 2012, The Journal of Biological Chemistry.

[59]  V. Kuchroo,et al.  IL-12 family cytokines: immunological playmakers , 2012, Nature Immunology.

[60]  Pascal Braun,et al.  History of protein–protein interactions: From egg‐white to complex networks , 2012, Proteomics.

[61]  R. Koenen,et al.  Touch of Chemokines , 2012, Front. Immun..

[62]  K. Preissner,et al.  Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. , 2012, American journal of respiratory and critical care medicine.

[63]  L. Varani,et al.  HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.

[64]  A. Christopoulos,et al.  Design and Receptor Interactions of Obligate Dimeric Mutant of Chemokine Monocyte Chemoattractant Protein-1 (MCP-1)* , 2012, The Journal of Biological Chemistry.

[65]  S. Takayama,et al.  Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. , 2012, The Biochemical journal.

[66]  Wuyuan Lu,et al.  α‐Defensins in human innate immunity , 2012, Immunological reviews.

[67]  T. Nevell,et al.  A copper-hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation. , 2011, Cytokine.

[68]  N. Heveker,et al.  Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways , 2011, Proceedings of the National Academy of Sciences.

[69]  J. Prestegard,et al.  Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. , 2011, Structure.

[70]  R. Koenen,et al.  CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment , 2011, Journal of thrombosis and haemostasis : JTH.

[71]  R. Koenen,et al.  Polymerization of MIP‐1 chemokine (CCL3 and CCL4) and clearance of MIP‐1 by insulin‐degrading enzyme , 2010, The EMBO journal.

[72]  C. Doglioni,et al.  Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T‐cell infiltration and positioning of malignant B cells , 2010, International journal of cancer.

[73]  Ariane L. Jansma,et al.  Characterization of the Chemokine CXCL11-Heparin Interaction Suggests Two Different Affinities for Glycosaminoglycans* , 2010, The Journal of Biological Chemistry.

[74]  Y. Xiong,et al.  Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family , 2010, Proteins.

[75]  Ariane L. Jansma,et al.  NMR Analysis of the Structure, Dynamics, and Unique Oligomerization Properties of the Chemokine CCL27* , 2010, The Journal of Biological Chemistry.

[76]  J. Shaw,et al.  Structural Basis of Chemokine Sequestration by a Tick Chemokine Binding Protein: The Crystal Structure of the Complex between Evasin-1 and CCL3 , 2009, PloS one.

[77]  M. Bianchi,et al.  HMGB1 loves company , 2009, Journal of leukocyte biology.

[78]  K. Rajarathnam,et al.  Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 Monomer and Dimer1 , 2009, The Journal of Immunology.

[79]  C. Weber,et al.  The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function. , 2009, Molecular immunology.

[80]  M. Shoham,et al.  Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. , 2009, New biotechnology.

[81]  M. Locati,et al.  Synergy‐inducing chemokines enhance CCR2 ligand activities on monocytes , 2009, European journal of immunology.

[82]  Christoph Seibert,et al.  Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.

[83]  Y. Sham,et al.  CXC and CC Chemokines Form Mixed Heterodimers , 2008, Journal of Biological Chemistry.

[84]  Osamu Yoshie,et al.  Extensive expansion and diversification of the chemokine gene family in zebrafish: Identification of a novel chemokine subfamily CX , 2008, BMC Genomics.

[85]  Brian F. Volkman,et al.  Interconversion between two unrelated protein folds in the lymphotactin native state , 2008, Proceedings of the National Academy of Sciences.

[86]  L. Fouser,et al.  An IL-17F/A Heterodimer Protein Is Produced by Mouse Th17 Cells and Induces Airway Neutrophil Recruitment , 2007, The Journal of Immunology.

[87]  Hongjun Jin,et al.  The Human CC Chemokine MIP-1β Dimer Is Not Competent to Bind to the CCR5 Receptor* , 2007, Journal of Biological Chemistry.

[88]  C. Weber,et al.  Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease , 2007, Circulation research.

[89]  T. Handel,et al.  Heterodimerization of CCR2 Chemokines and Regulation by Glycosaminoglycan Binding* , 2006, Journal of Biological Chemistry.

[90]  A. Proudfoot,et al.  The biological relevance of chemokine-proteoglycan interactions. , 2006, Biochemical Society transactions.

[91]  Silvia Sebastiani,et al.  A rich chemokine environment strongly enhances leukocyte migration and activities. , 2005, Blood.

[92]  M. Uguccioni,et al.  CCL22‐induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first β‐strand of chemokine , 2005, European journal of immunology.

[93]  Guoping Wu,et al.  Platelet Factor 4 and Interleukin-8 CXC Chemokine Heterodimer Formation Modulates Function at the Quaternary Structural Level* , 2005, Journal of Biological Chemistry.

[94]  Christopher Chin,et al.  Dimer Dissociation Is Essential for Interleukin-8 (IL-8) Binding to CXCR1 Receptor* , 2004, Journal of Biological Chemistry.

[95]  Yusuke Nakamura,et al.  Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro , 2004, Nature.

[96]  F. Petersen,et al.  Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases, whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. , 2004, Blood.

[97]  F. Mach,et al.  Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.

[98]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[99]  Arkadiusz Z Dudek,et al.  Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. , 2003, Blood.

[100]  A. Imberty,et al.  A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization. , 2002, Biochemistry.

[101]  M. Farzan,et al.  The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1α Association and HIV-1 Entry* , 2002, The Journal of Biological Chemistry.

[102]  J. Markley,et al.  Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. , 2001, Biochemistry.

[103]  M. Norcross,et al.  Identification of Human Macrophage Inflammatory Proteins 1α and 1β as a Native Secreted Heterodimer* , 2001, The Journal of Biological Chemistry.

[104]  A. Trkola,et al.  The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity* , 2001, The Journal of Biological Chemistry.

[105]  K. Ley,et al.  RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium , 2001, Circulation.

[106]  P. Roey,et al.  Three-dimensional structure of human follicle-stimulating hormone. , 2001, Molecular endocrinology.

[107]  D. Spillmann,et al.  Characterization of a Neutrophil Cell Surface Glycosaminoglycan That Mediates Binding of Platelet Factor 4* , 1999, The Journal of Biological Chemistry.

[108]  K. Jarnagin,et al.  Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B* , 1998, The Journal of Biological Chemistry.

[109]  H. Flad,et al.  A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. , 1998, Journal of immunology.

[110]  D. Spillmann,et al.  Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[111]  B D Sykes,et al.  1H NMR solution structure of an active monomeric interleukin-8. , 1995, Biochemistry.

[112]  K. Mayo,et al.  Subunit association and structural analysis of platelet basic protein and related proteins investigated by 1H NMR spectroscopy and circular dichroism. , 1994, The Journal of biological chemistry.

[113]  L. Chen,et al.  Crystal structure of recombinant human platelet factor 4. , 1994, Biochemistry.

[114]  B. Sykes,et al.  Neutrophil activation by monomeric interleukin-8 , 1994 .

[115]  A. Zernecke,et al.  Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice , 2009, Nature Medicine.

[116]  B. Volkman,et al.  Chapter 3. Lymphotactin structural dynamics. , 2009, Methods in enzymology.

[117]  Christian Weber,et al.  Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. , 2005, Blood.

[118]  Elias Lolis,et al.  Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.

[119]  J. Lubkowski,et al.  The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions , 1997, Nature Structural Biology.